<span item_type="fundamental" item_id="86b1056dafe9d00c59b771c560a7e4ae" counter_id="ST/US/OTLK" env="prod"></span><span item_type="announcement" item_id="595494505587350401" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 1.414 M.</p><p>EPS: As of FY2025, the actual value is USD -1.79, missing the estimate of USD -1.6425.</p><p>EBIT: As of FY2025, the actual value is USD -66.87 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Revenue from sales of LYTENAVA in Germany and the UK was $1.4 million for the year ended September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Net loss for the year ended September 30, 2025 was $62.4 million, compared to a net loss of $75.4 million for the year ended September 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm"></span></li><li>Research and development expenses decreased by $14.6 million to $27.2 million for the year ended September 30, 2025, primarily due to reduced expenses associated with the NORSE EIGHT clinical trial.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm"></span></li><li>Selling, general and administrative expenses increased by $10.0 million to $39.9 million for the year ended September 30, 2025, driven by increased launch-related expenses for LYTENAVA in Europe and higher compensation costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities was $51.8 million for the year ended September 30, 2025, compared to $68.8 million for the year ended September 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm"></span></li><li>Net cash provided by financing activities was $45.0 million for the year ended September 30, 2025, primarily from proceeds of $33.1 million from the issuance of the March 2025 Note and $16.8 million from warrant exercises.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Inventory increased by $3.3 million during the year ended September 30, 2025, reflecting commercial inventory manufactured during the period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>The company plans to focus on supporting the review of its BLA submission for ONS-5010/LYTENAVA with the FDA and preparing for potential launch to generate commercial revenues.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm"></span></li><li>Management is evaluating various strategic opportunities to obtain required funding for future operations, including potential licensing arrangements, private placements, and public offerings.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm"></span></li></ul>

Outlook Therapeutics | 10-K: FY2025 Revenue: USD 1.414 M